Skip to main content

X-linked Retinoschisis clinical trials at UCSF
1 in progress, 1 open to new patients

  • Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

    open to eligible males ages 6 years and up

    This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.

    San Francisco, California and other locations